A new review from Beijing Chest Hospital, Capital Medical University, systematically expounds the dual role of DNA repair core protein Rad51 in tumors. This article reveals that Rad51 not only maintains genomic stability through homologous recombination repair, but its overexpression is also closely related to chemotherapy, radiotherapy and PARP inhibitor resistance in various cancers. Most importantly, the review delves deeply into how Rad51 shapes the tumor immune microenvironment by regulating the cGAS-STING pathway, influencing neoantigen generation and PD-L1 expression, providing a new theoretical basis for the anti-cancer strategy of combining Rad51 with immune checkpoint inhibitors.

A comprehensive review by Professor Dong's research group, published in eGastroenterology, delineates the intertwined mechanisms linking steatotic liver disease (SLD) and cancer. It highlights the genetic, metabolic, and immunological factors driving disease progression from steatosis to hepatocellular carcinoma (HCC). The authors summarize emerging therapeutics—thyroid hormone receptor β agonists, GLP-1-based poly-agonists, FGF21 analogues, and FXR modulators—offering hope for SLD and related malignancies.

Ampullary adenocarcinoma (AAC), a rare gastrointestinal malignancy, presents major therapeutic challenges due to its biological complexity and high recurrence rates.

Penile squamous cell carcinoma (PSCC) is a rare but aggressive malignancy that severely affects men’s health worldwide.

In a new study, coauthors Jordan Yaron, Kaushal Rege and their colleagues with the Biodesign Center for Biomaterials Innovation and Translation discovered that the protein SerpinB3 is part of the body’s natural wound-healing arsenal, helping the skin recover after damage. 

The research points to new possibilities: Boosting it could improve wound healing, while blocking it may offer a way to fight aggressive cancers. The findings may also help explain SerpinB3’s role in inflammatory ailments, from skin conditions to asthma.

A new molecule developed by researchers at Oregon Health & Science University offers a promising avenue to treat intractable cases of triple-negative breast cancer — a form of cancer that is notoriously aggressive and lacks effective treatments.

A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast cancer, according to new research published in the November issue of The Journal of Nuclear Medicine. The regimen, which pre-treats the tumor before delivering targeted alpha-radioimmunotherapy, resulted in durable major responses--including histologic cures--with minimal toxicities, paving the way for a safer and more effective treatment option for breast cancer patients.

The University of Cincinnati Cancer Center’s Trisha Wise-Draper, MD, PhD, will present early data from a Phase 2 clinical trial showing a combination of immunotherapy medications can activate a robust immune response and help overcome treatment resistance in patients with refractory melanoma at the Society for Immunotherapy of Cancer 40th Anniversary Annual Meeting Nov. 7.

A comprehensive review in Current Molecular Pharmacology reveals how TCF/LEF proteins control Wnt signaling through dynamic enhanceosome assembly, post-translational modifications, and isoform diversity. The study highlights the clinical success of TNIK inhibitor INS018_055 in idiopathic pulmonary fibrosis, marking a breakthrough in targeting previously "undruggable" Wnt pathway components.